Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | DHODH | Q02127 | 4/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.42 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.42 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787380 | 0.87 | MEN1 (0.52) | TERTAKR1C2AKR1C3DHODHKCNK2 | |
| SCHEMBL6785899 | 0.84 | TERT (0.54) | TERTDHODHKCNK2LTB4R | |
| SCHEMBL6785956 | 0.83 | TERT (0.53) | TERTDHODHKCNK2LTB4R | |
| SCHEMBL6783990 | 0.83 | TERT (0.47) | TERTDHODHKCNK2LTB4RDEGS1 | |
| SCHEMBL4020296 | 0.82 | TERT (0.77) | TERTDHODHKCNK2LTB4RDEGS1 | |
| SCHEMBL6788013 | 0.81 | TERT (0.62) | TERTAKR1C2AKR1C3DHODHKCNK2 | |
| SCHEMBL6781608 | 0.81 | CYP3A4 (0.53) | TERTAKR1C2AKR1C3KCNK2LTB4R | |
| SCHEMBL6784789 | 0.81 | SERPINE1 (0.53) | TERTDHODHKCNK2DEGS1 | |
| SCHEMBL6785402 | 0.80 | TERT (0.60) | TERTAKR1C2AKR1C3DHODHKCNK2 | |
| SCHEMBL6784709 | 0.80 | TERT (0.46) | TERTDHODHKCNK2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727250-B2 | ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-04-27 | — | — | US | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | TERT 1/4885AKR1C2 1036/4885AKR1C3 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.